Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
-
LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
-
LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
-
LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
-
--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with...
-
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory...
-
KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal...
-
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company...
-
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
-
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the...